资料单张
MIPRALIN 10 mg TABLETS
MIPRALIN 25 mg TABLETS
SCHEDULING STATUS:
S5
PROPRIETARY NAME
(and dosage form)
MIPRALIN 10 mg TABLETS
MIPRALIN 25 mg TABLETS
COMPOSITION:
Tablets containing 10 mg and 25 mg
imipramine hydrochloride
.
PHARMACOLOGICAL CLASSIFICATION:
A 1.2 Psychoanaleptics (antidepressants)
PHARMACOLOGICAL ACTION:
Imipramine hydrochloride is a
tricyclic antidepressant
. It has weak anti-cholinergic and antihistaminic actions and
prevents the uptake of catecholamines at adrenergic nerve endings. Its mode of action in depression is not fully
understood. Its therapeutic effects are only evident after 2 - 3 weeks.
Imipramine is readily absorbed from the gastrointestinal tract and about 95 % becomes reversibly bound to plasma
proteins.
INDICATIONS:
Endogenous depressive states and depression associated with other psychiatric conditions.
Mipralin has been reported to be of value in the treatment of enuresis in childhood.
CONTRA-INDICATIONS:
The acute phase of myocardial infarction. Administration is not advised during the first trimester of pregnancy, unless
there are compelling reasons for its use.
DOSAGE AND DIRECTIONS FOR USE:
In the treatment of depression:
25 to 75 mg thrice daily; elderly patients may require only 10 to 30 mg daily.
When a satisfactory response is obtained, the drug should be withdrawn gradually, but prolonged maintenance treatment
may be necessary in some cases.
In the treatment of enuresis, the usual dose for children over 10 years of age is 50 mg at bedtime, and for children aged 4
to 10 years, 25 mg at bedtime.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Peripheral anticholinergic side effects; notably dry mouth, constipation, urinary retention and pupillary dilation with
blurred vision and changes in visual accommodation. When anticholinergic effects are severe t
阅读完整的文件
资料单张 